Validation of the Bronchiectasis Severity Index in alpha-1 antitrypsin deficiency
Joshua De Soyza, Paul Ellis, Daniella Spittle, Anita Pye, Alice M Turner · 2026
Read Validation of the Bronchiectasis Severity Index in alpha-1 antitrypsin deficiency by Joshua De Soyza, Paul Ellis, Daniella Spittle, Anita Pye, Alice M Turner (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0355956.txt.
Description
Joshua De Soyza leads a team of five checking whether a standard lung severity score works in a genetic lung disease, in PLOS ONE in 2026. Alpha-1 antitrypsin deficiency damages lungs and often brings bronchiectasis, chronically widened airways. A widely used severity index predicts death, hospitalization, and flare ups in ordinary bronchiectasis, but it had never been tested in this population. The team applied it to one hundred ninety-eight registry patients in Birmingham, nearly all with the severe genotype and most with COPD alongside.
The index sorted patients meaningfully. Survival differed significantly across its severity bands, exactly what a prognostic tool must do. The team also probed whether scores tracked lung function decline and quality of life measures. Validation in a rare disease subgroup matters because trials and clinics borrow tools from common diseases on faith. Here, at least for prognosis, the borrowed tool earned its place.
Catalog record
| CREATOR | Joshua De Soyza, Paul Ellis, Daniella Spittle, Anita Pye, Alice M Turner |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24413 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |